SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet. 2005; 365: 1159-1162.
  • 2
    Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996; 276: 637-639.
  • 3
    Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001; 357: 1191-1194.
  • 4
    Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials [serial online]. PLoS Med. 2010; 7: e1000251.
  • 5
    Schulz KF, Altman DG, Moher D; Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials [serial online]. BMC Med. 2010; 8: 18.
  • 6
    Lai TY, Wong VW, Lam RF, Cheng AC, Lam DS, Leung GM. Quality of reporting of key methodological items of randomized controlled trials in clinical ophthalmic journals. Ophthalmic Epidemiol. 2007; 14: 390-398.
  • 7
    Scales CD Jr, Norris RD, Preminger GM, Vieweg J, Peterson BL, Dahm P. Evaluating the evidence: statistical methods in randomized controlled trials in the urological literature. J Urol. 2008; 180: 1463-1467.
  • 8
    Mills E, Wu P, Gagnier J, Heels- Ansdell D, Montori VM. An analysis of general medical and specialist journals that endorse CONSORT found that reporting was not enforced consistently. J Clin Epidemiol. 2005; 58: 662-667.
  • 9
    Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed [serial online]. BMJ. 2010; 340: c723.
  • 10
    Cherny NI, Abernethy AP, Strasser F, Sapir R, Currow D, Zafar SY. Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systematic review. J Clin Oncol. 2009; 27: 5476-5486.
  • 11
    Kober T, Trelle S, Engert A. Reporting of randomized controlled trials in Hodgkin lymphoma in biomedical journals. J Natl Cancer Inst. 2006; 98: 620-625.
  • 12
    Pat K, Dooms C, Vansteenkiste J. Systematic review of symptom control and quality of life in studies on chemotherapy for advanced non-small cell lung cancer: how CONSORTed are the data? Lung Cancer. 2008; 62: 126-138.
  • 13
    Sut N, Senocak M, Uysal O, Koksalan H. Assessing the quality of randomized controlled trials from 2 leading cancer journals using the CONSORT statement. Hematol Oncol Stem Cell Ther. 2008; 1: 38-43.
  • 14
    Ziogas DC, Zintzaras E. Analysis of the quality of reporting of randomized controlled trials in acute and chronic myeloid leukemia, and myelodysplastic syndromes as governed by the CONSORT statement. Ann Epidemiol. 2009; 19: 494-500.
  • 15
    Allegra C, Blanke C, Buyse M, et al. End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol. 2007; 25: 3572-3575.
  • 16
    Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist. 2008; 13( suppl 2): 19-21.
  • 17
    Farrell AT, Pazdur R, von Eschenbach AC. Expediting the availability of drugs for US patients with cancer. Nat Clin Pract Urol. 2008; 5: 654-656.
  • 18
    Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355: 1041-1047.
  • 19
    de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18: 2938-2947.
  • 20
    Johnson KR, Ringland C, Stokes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 2006; 7: 741-746.
  • 21
    Comella P, Crucitta E, De Vita F, et al. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group. Ann Oncol. 2002; 13: 866-873.
  • 22
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
  • 23
    Tolcher AW. Stable disease is a valid endpoint in clinical trials. Cancer J. 2009; 15: 374-378.
  • 24
    DerSimonian R, Charette LJ, McPeek B, Mosteller F. Reporting on methods in clinical trials. N Engl J Med. 1982; 306: 1332-1337.
  • 25
    Zelen M. Guidelines for publishing papers on cancer clinical trials: responsibilities of editors and authors. J Clin Oncol. 1983; 1: 164-169.
  • 26
    Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy endpoints in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007; 25: 2127-2132.
  • 27
    Chua YJ, Sargent D, Cunningham D. Definition of disease-free survival: this is my truth-show me yours. Ann Oncol. 2005; 16: 1719-1721.